Neil Kumar sold $3.4M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 101,156 shares at an average of $33.38, traded May 19, 2025, filed May 20, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.4M at market
- +10Share of holdings soldSold 42% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-075425, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 16, 2025 | MOption exercise Common Stock10b5-1 | +64,696 | - | - | 276,414 | May 20, 2025 |
| May 16, 2025 | FTax withholding Common Stock10b5-1 | -32,854 | $33.84 | $1.1M | 243,560 | May 20, 2025 |
| May 19, 2025 | SOpen-market sale Common Stock10b5-1 | -25,756 | $33.32 | $858k | 217,804 | May 20, 2025 |
| May 19, 2025 | SOpen-market sale Common Stock10b5-1 | -400 | $33.75 | $13k | 217,404 | May 20, 2025 |
| May 20, 2025 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -75,000 | $33.40 | $2.5M | 4,798,447 | May 20, 2025 |
| May 16, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -33,544 | $0.00 | $0 | 234,808 | May 20, 2025 |
| May 16, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -19,599 | $0.00 | $0 | 215,592 | May 20, 2025 |
| May 16, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -11,553 | $0.00 | $0 | 173,307 | May 20, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 28Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.2M 30,011 shares | -12% | |
| 14Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $149k 2,000 shares | -2% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.9M 80,000 shares | -10% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.7M 26,156 shares | -10% | |
| 25Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $666k 10,000 shares | -46% | |
| 75Notable | BridgeBio Pharma, Inc. | Andrew Lo director | $6.3M 95,599 shares | -175% | |
| 42Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $1.1M 16,934 shares | -4% | |
| 60Notable | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.0M 80,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.